Adolescent Fitness Tied to Cardiometabolic Health Years Later
23 Jan 2024
Clinical Result
TUESDAY, Jan. 23, 2024 -- Adolescent fitness is inversely associated with the burden of cardiometabolic conditions up to 45 years later, according to a study published online in the January issue of the Scandinavian Journal of Medicine & Science in Sports.
Perttu T.T. Laakso, from the University of Jyväskylä in Finland, and colleagues examined the effect of adolescent cardiorespiratory fitness (CRF), muscular fitness (MF), and speed-agility fitness (SA) on middle-aged cardiometabolic disease risk. The analysis included participants evaluated in adolescence (12 to 19 years) and early (37 to 44 years) or late (57 to 64 years) middle age.
The researchers found that adolescent CRF was inversely associated with middle-age accumulated burden of cardiometabolic conditions, regardless of adiposity, in the whole sample (ß = −0.10) and with elevated blood pressure in women (odds ratio, 0.71). Overall, the associations were stronger in women than men. There was an inverse association of adolescent MF and SA with middle-aged waist circumference, but it did not show as consistent associations as with CRF.
"There have been publicly discussed concerns over how the deteriorating fitness of young people will affect the future labor force. This study gives us some scientific evidence to support that concern," Laakso said in a statement. "Unfortunately, there is little sign of this concern being alleviated, given that the cardiorespiratory fitness level among today’s adolescents has been shown to be significantly lower than that of the adolescents examined in this study."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.